India’s $58B Pharma Market Eyes $450B by 2047: Chronic Therapies & Local Manufacturing Drive Growth

The Indian pharmaceutical market (IPM) begins 2025 at an estimated value of US$58 billion. Growth is shaped by demographic trends, rising demand for chronic disease treatments, and ongoing government measures to expand local manufacturing capacity. Current projections suggest the market could reach US$120–130 billion by 2030 and approach US$450 billion by 2047, reflecting a long-term structural shift in the industry.

Market Growth Increases With Strong Domestic Demand: India Ranks 3rd in Pharma Production by Volume, 14th by Value

In August 2025, the Indian pharmaceutical market posted an 8.1% year-on-year increase. Revenue is expected to grow between 8-9% in FY26, a pace that places India among the fastest expanding markets worldwide. India currently ranks third globally in pharmaceutical production by volume and fourteenth by value. The country produces more than half of the world’s vaccines and generic medicines used in the United States. As a starting point, India operates the largest number of USFDA-approved pharma plants outside the United States, with recent tallies in the ~500–650 range depending on definitions and timing. That footprint underwrites global supply in generics, biologics, and APIs—and puts inspection quality and compliance in sharp focus for the next phase.

Within this landscape sits the Serum Institute of India, the world’s largest vaccine manufacturer. Capable of producing more than 4 billion doses annually—including measles, polio, HPV, and most recently the R21 malaria vaccine—it demonstrates India’s ability to operate at unmatched scale. Unlike listed pharmaceutical giants, its private ownership has allowed it to prioritize affordability, supplying life-saving vaccines across Africa, Asia, and beyond. While this dominance has been built on high-volume generics, policymakers are steering the industry toward greater value creation.

India’s policy push reflects an attempt to move from sheer production volume to higher-value innovation and resilience. The BioE3 policy (Biotechnology for Economy, Environment, and Employment), cleared by the Cabinet in August 2024, targets sustainable biomanufacturing and ties directly to a circular bioeconomy. In practice, this has meant DBT and BIRAC launching high-performance biomanufacturing platforms that allow startups and researchers to scale processes from lab to pilot plants more quickly. The aim is not only greener production but also greater independence from external supply shocks.

Complementing this, the National Biopharma Mission—co-funded with the World Bank—continues to de-risk early development for vaccines, biosimilars, devices, and diagnostics. By sharing development risk and validation costs, it lowers barriers for Indian firms to move candidates through preclinical and early clinical stages, a critical gap where many projects would otherwise stall.

Chronic Therapies Grow 12% Outpacing Acute Segments

Looking at the pharmaceutical giants in the Indian industry, players are focusing their attention on several key areas. Whilst neuropsychiatry tops the charts in terms of sales, cardiovascular disease is a common therapeutic focus area. According to a WHO India Report, the age-adjusted CVD death rate is 349 per 100,000 in men and 265 per 100,000 in women [12-14]. Women’s health tops the charts in the sales as well. Overall, more than 58% of children aged 6–59 months were anaemic, with haemoglobin (Hb) concentrations of <11 g/dL. Anaemia was more prevalent in children living in rural areas than urban areas, which is mainly related to mothers with little or no education and households of low wealth status. 

One of the defining shifts in 2025 is the rise of chronic therapies. Treatments for long-term conditions such as diabetes, cardiovascular disease, and central nervous system disorders expanded by 12% in August, double the 6% growth of acute therapies like anti-infectives and gastrointestinal drugs. This reflects the rising prevalence of lifestyle-related illnesses in India and the growing need for sustained treatment rather than short-term interventions.

Company Hierarchy and Sales Breakdown (2025)

The domestic pharmaceutical market in 2025 is dominated by a few key players, with a clear hierarchy emerging based on formulation sales and market share. Sun Pharma leads the pack, followed by a tier of major competitors. The following table, compiled from the available data on market performance, provides a clear overview of the market leaders.

The rankings further illustrate a distinct concentration of market power among the top four companies, which collectively account for over 25% of the total market share.

The Indian pharmaceutical market in 2025 is not just growing but evolving. Strong domestic demand, a decisive shift toward chronic therapies, and forward-looking government policies are building a resilient foundation. While global challenges, especially in the United States, present obstacles, the industry’s investments in innovation and quality improvement are setting the stage for long-term success. With projections pointing to $130B by 2030, India’s pharmaceutical sector is likely to see the greatest contribution from the biologics and advanced therapies CDMO sector, particularly Antibody Drug Conjugates (ADCs), gene therapies, and RNA therapeutics. This growth is driven by a strong foundation in small molecule manufacturing, increasing global demand for complex biologics, and strategic shifts by global pharmaceutical companies to outsource high-value, innovative drug development. The Indian government’s Production-Linked Incentive (PLI) scheme further supports this shift by incentivizing the production of advanced, high-tech pharmaceuticals, including biopharmaceuticals.  

Author

[email protected]